Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018
21. Mai 2018 06:00 ET
|
Tetraphase Pharmaceuticals, Inc.
– Four Abstracts Selected for Poster Presentations – – Presentations Include New Eravacycline Pooled Analysis of IGNITE 1 and IGNITE4 and Data Highlighting the Pre-Clinical Activity of TP-6076 – ...
Tetraphase Pharmaceuticals to Present at the UBS Global Healthcare Conference
09. Mai 2018 06:30 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights
03. Mai 2018 16:30 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
19. April 2018 07:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases
12. April 2018 07:00 ET
|
Tetraphase Pharmaceuticals, Inc.
– Phase 3 IGNITE4 Results in Complicated Intra-Abdominal Infection Recognized as a ‘Best Rated Abstract’ – – Other Key Eravacycline and TP-6076 Data to Also be Highlighted – WATERTOWN, Mass., April ...
Tetraphase Pharmaceuticals to Present at H.C. Wainwright Annual Global Life Sciences Conference
02. April 2018 07:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals to Present at 17th Annual Needham Healthcare Conference
20. März 2018 16:01 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results, Highlights Achievements and Key 2018 Milestones
06. März 2018 16:40 ET
|
Tetraphase Pharmaceuticals, Inc.
Achieved positive results of Eravacycline in Phase 3 IGNITE 4 clinical trial for cIAI Filed NDA in US for IV Eravacycline for cIAI and PDUFA date is August 28th Raised over $65 million through...
Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer
01. März 2018 16:01 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Announces FDA Acceptance for Filing of its NDA Submission for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
27. Februar 2018 08:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...